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Accurate diagnosis and typing of renal amyloidosis is critical
for prognosis, genetic counseling, and treatment. Laser
microdissection and mass spectrometry are emerging
techniques for the analysis and diagnosis of many renal
diseases. Here we present the results of laser microdissection
and mass spectrometry performed on 127 cases of renal
amyloidosis during 2008–2010. We found the following
proteins in the amyloid deposits: immunoglobulin light and
heavy chains, secondary reactive serum amyloid A protein,
leukocyte cell–derived chemotaxin-2, fibrinogen-a chain,
transthyretin, apolipoprotein A-I and A-IV, gelsolin, and b-2
microglobulin. Thus, laser microdissection of affected areas
within the kidney followed by mass spectrometry provides
a direct test of the composition of the deposit and forms
a useful ancillary technique for the accurate diagnosis and
typing of renal amyloidosis in a single procedure.
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Amyloidosis is caused by extracellular deposition of proteins
in an insoluble beta-pleated physical conformation. Amyloid
deposits are identified based on their apple-green birefrin-
gence under a polarized light microscope on Congo red stains
and the presence of rigid, non-branching fibrils 7.5–10 nm in
diameter on electron microscopy.1,2 The most common
forms of systemic amyloidosis are immunoglobulin light-
chain (AL) amyloidosis and reactive secondary amyloidosis
(AA) due to chronic inflammatory diseases (e.g., rheumatoid
arthritis and chronic infections). Hereditary or familial
amyloidosis is another group of amyloidoses that is being
diagnosed with increasing frequency and includes the
amyloid derived from leukocyte cell–derived chemotaxin-2
(LECT2), fibrinogen-a chain, transthyretin (TTR), lysozyme,
and apolipoproteins.3,4
Accurate typing of amyloidosis has implications for
prognosis, genetic counseling, and treatment. Although renal
biopsy can type AL and AA amyloidosis with the use of
immunofluorescence and immunohistochemistry studies,
some cases pose problems in accurate typing of amyloid,
and ancillary tests including genetic analysis are often
required. Heavy-chain amyloidosis and many forms of
hereditary amyloidosis are particularly difficult to type on
routine renal biopsy studies.5,6 We have recently reported on
the technique of laser microdissection (LMD) and tandem
mass spectrometry (MS)–based proteomic analysis as a
sensitive and specific tool for the diagnosis of amyloidosis.7,8
In this report, we describe in detail the LMD/MS results of
127 cases of renal amyloidosis performed over a 2-year period
(2008–2010). We also describe and discuss the value of LMD/
MS as an important ancillary test for both the diagnosis
and typing of renal amyloidosis.
RESULTS
LMD/MS was performed on 127 renal biopsy and/or
nephrectomy specimens for diagnosis and typing of
renal amyloidosis. The results are summarized in Table 1.
Glomeruli, interstitium, or vessels were microdissected for
MS studies (Figure 1).
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AL amyloidosis, lambda light chain
Thirty-four cases of AL amyloidosis associated with
immunoglobulin (Ig) lambda light chain deposition were
diagnosed based on LMD/MS results. This was by far the
largest group. Ig lambda light-chain constant region (I, II,
and/or III) was present in all cases, with 495% probability
(Figure 2a). The spectra for lambda light-chain constant
region varied from 2 to 55, with an average of 8.5 spectra
(±8.7; Figure 3a). Eighteen cases also showed spectra for Ig
lambda light-chain variable (V) region (with 495% pro-
bability) in addition to the Ig lambda light-chain constant
(C) region: 11 cases showed the Ig lambda light-chain V–III
region, 6 cases showed the V–I region (Figure 3b), 6 cases
showed the V–II region, and 6 cases showed the V–VI region.
In 15 cases, a small number of spectra for IgG1, IgG2, or IgG3
was present with probability495%. In all cases, large spectra
of apolipoprotein E protein were present (with probability
495%), whereas serum amyloid P component (SAP) was
present in 31 cases with probability 495% and in 2 cases
with probability480–94%. In the one SAP-negative case, the
sample size was suboptimal even though MS/MS clearly showed
only Ig lambda light-chain constant region with 495%
probability and the absence of Ig kappa light chains or other
heavy chains. In all cases, MS failed to detect peptides
representing LECT2, serum amyloid A (SAA), fibrinogen-a,
lysozyme, TTR, or gelsolin.
AL amyloidosis, kappa light chain
Twenty cases of AL amyloidosis associated with Ig kappa
light chain deposition were diagnosed based on LMD/MS
results. Ig kappa light-chain C region was present in all cases
with 495% probability (Figure 2). The spectra for the
Ig kappa light-chain C region varied from 5 to 37, with
an average of 21.5 spectra (±16.8; Figure 3c). Seven cases
also showed spectra for Ig kappa light-chain V region (with
495% probability) in addition to the Ig kappa light-
chain C region: five cases showed the Ig kappa light-chain
V–I region, one case showed the V–III region, and one case
showed the V–IV region. In 13 cases, a small number of
spectra for IgG1, IgG2, or IgG4 were also present, with a
probability ranging from 80 to 495%. In all cases, large
spectra (with probability495%) of apolipoprotein E protein
and SAP were present. In all cases, MS failed to detect
peptides representing LECT2, SAA, fibrinogen-a, lysozyme,
TTR, or gelsolin.
Heavy-chain amyloidosis and heavyþ light-chain amyloidosis
Thirteen cases of Ig heavy-chain (AH) amyloidosis or mixed
AHþAL amyloidosis were diagnosed based on LMD/MS
results. Of these, six cases showed only AH amyloid (Figure 2)
and seven cases showed AHþAL amyloidosis. The following
spectra were noted in the six cases that showed AH amyloid:
three cases showed spectra for the IgG1 C region, one case
showed spectra for the IgG1 C region and the Ig heavy-chain
V region, one case showed spectra for IgG-1 and IgG-3
(Figure 3d and e), and one case showed spectra for only Ig
heavy-chain V region (in all cases, probability was 495%).
The following spectra were noted in the seven cases that
showed AHþAL amyloid: three cases showed the IgG1 C
regionþ Ig lambda light-chain C region, two cases showed
the IgG1 C regionþ Ig kappa light-chain C region, and two
cases showed the IgA C region, one with Ig lambda light-
chain C region and the other with Ig kappa light-chain C
region (in all cases, the probability was 495%). In all cases,
large spectra (probability 495%) of apolipoprotein E
protein, as well as SAP, were present. MS failed to detect
peptides representing LECT2, SAA, fibrinogen-a, lysozyme,
TTR, or gelsolin in any of the cases.
AA amyloidosis
Sixteen cases of AA amyloidosis were diagnosed based on
LMD/MS results. LMD/MS of AA amyloid cases showed a
Table 1 | Renal amyloidosis typing based on mass
spectrometry results
Amyloid type
Number of cases
(%)
AL, lambda light-chain amyloidosis 34 (26.77)
AL, kappa light-chain amyloidosis 20 (15.74)
Heavy-chain amyloidosis and heavy+light-chain
amyloidosis
13 (10.02)
AA amyloidosis 16 (12.5)
Fibrinogen A-a amyloidosis 7 (5.5)
Lect-2 amyloidosis 26 (20.4)
Apolipoprotein amyloidosis 2 (1.57)
Gelsolin amyloidosis 2 (1.57)
b-2 Microglobulin 1 (0.8)
TTR amyloidosis 1 (0.8)
Indeterminate 5 (3.9)a
Abbreviations: AA, reactive secondary; AL, immunoglobulin light-chain amyloidosis;
TTR, transthyretin.
aOn retrospective review of the mass spectrometry data, three of the five cases
qualify as apolipoprotein A-IV amyloidosis.
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Figure 1 | Laser microdissection. Congo red–positive (a)
glomeruli, (b) vessels, and (c) interstitium marked for micro-
dissection. (d) Empty space following microdissection of glomeruli
from a.
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large number of spectra of SAA protein in all cases (Figure 2).
The range was from 15 to 79 spectra, with an average of
46.14 spectra (±19.4) with 495% probability in all cases
(Figure 3f). In all cases, large spectra (probability 495%)
of apolipoprotein E protein were also present. SAP was also
present in all cases; the spectra ranged from 5 to 32, with an
228 Kidney International (2012) 82, 226–234
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Figure 3 |Percentage sequence (peptide) coverage. Representative sequence (peptide) coverage of the protein detected in the
microdissected sample showing: (a) 15 total spectra, 6 unique spectra, and 5 unique peptides for 64% coverage of Ig lambda light-chain
constant region with 100% probability; (b) 8 total spectra, 2 unique spectra, and 2 unique peptides for 15% coverage of Ig lambda light
chain variable I region with 100% probability; (c) 18 total spectra, 6 unique spectra, and 4 unique peptides for 64% coverage of Ig kappa
light-chain constant region with 100% probability; (d) 4 total spectra, 2 unique spectra, and 2 unique peptides for 19% coverage of IgG1
heavy constant chain with 100% probability; (e) 5 total spectra, 3 unique spectra, and 3 unique peptides for 8% coverage of IgG3 heavy
constant chain with 100% probability; (f) 37 total spectra, 7 unique spectra, and 6 unique peptides for 35% coverage of serum amyloid A
(SAA) protein with 100% probability; (g) 42 total spectra, 11 unique spectra, and 10 unique peptides for 10% coverage of fibrinogen-a
protein with 100% probability; (h) 11 total spectra, 4 unique spectra, and 4 unique peptides for 23% coverage of LECT2 with 100%
probability; (i) 33 total spectra, 16 unique spectra, and 16 unique peptides for 17% coverage of gelsolin protein with 100% probability;
(j) 11 total spectra, 7 unique spectra, and 5 unique peptides for 32% coverage of b-2 microglobulin with 100% probability; and (k) 37 total
spectra, 16 unique spectra, and 14 unique peptides for 63% coverage of transthyretin (TTR) with 100% probability. The yellow highlighted
areas show the actual peptides detected by the mass spectrometry, and the green highlighted areas show oxidized or methylated
amino acids.
Figure 2 |Mass spectrometry by spectra. (a) Representative mass spectrometry data by spectral analyses from a case of AL lambda
light-chain amyloidosis (AL-lambda), AL kappa light-chain amyloidosis (AL-kappa), heavy-chain amyloidosis (AH), AA amyloidosis (AA),
fibrinogen-a amyloidosis (AFib), LECT-2 amyloidosis (ALect2), transthyretin (TTR) amyloidosis (ATTR), gelsolin amyloidosis (AGel), and
apolipoprotein A-IV amyloidosis (ApoAIV). The probability number (495% is highlighted in green, 80–94% in yellow) indicates essentially
the percent homology between peptides detected in the specimens and the published amino-acid sequences of their corresponding
proteins. VOR, NEWM, and Rei are names that have been given to specific sequences of variable regions. (b) Representative mass
spectrometry data from a case of fibrinogen-a amyloidosis showing both the fibrinogen-a chain and the mutated fibrinogen-a peptide.
(c) Representative mass spectrometry data from day 0 protocol allograft biopsies in seven cases. Red star indicates shared peptides between
different proteins. Ig, immunoglobulin.
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average of 16.6 spectra (±7.5). In addition, in one case,
MS/MS also detected a variant SAA protein (SAA W71R)
similar to that described by Møyner K et al.9,10 Small
amounts of IgG with polytypic Ig lambda and kappa light
chains were noted in almost half the cases. MS failed to detect
peptides representing LECT2, fibrinogen-a, lysozyme, TTR,
apolipoprotein A-I, or gelsolin in any of the cases.
Fibrinogen-a amyloidosis
Seven cases of fibrinogen-a amyloidosis were diagnosed
based on LMD/MS results. LMD/MS showed a large number
of spectra of fibrinogen-a chain in all cases, with 495%
probability (Figure 2). The range was from 18 to 109 spectra,
with an average of 55.2 spectra (±21.51; Figure 3g). In
addition, MS also identified the mutated fibrinogen-a chain
with 495% probability in all cases (Figure 2b). In all cases,
large spectra (with 495% probability) of apolipoprotein E
protein were also present. SAP was also present in all cases;
the spectra ranged from 7 to 40, with an average of 20.2
spectra (±7.5). Small amounts of IgG with polytypic Ig
lambda and kappa light chains were also noted in half the
cases. MS failed to detect peptides representing LECT2, SAA,
lysozyme, TTR, apolipoprotein A-I, or gelsolin in any of the
cases.
LECT2 amyloidosis
Twenty-six cases of LECT2 amyloidosis were diagnosed based
on LMD/MS results. LMD/MS of LECT2 amyloid cases
showed a large number of spectra of LECT2 protein in 25 of
26 cases, with 495% probability in these cases (Figure 2).
In one case, repeat LMD/MS showed only one unique LECT2
spectrum (with a probability of 80–94%). The range was from
2 to 16 spectra, with an average of 7.6 spectra (±3.8) with
495% probability in all cases (Figure 3h), except for the one
case mentioned above. Large spectra of apolipoprotein E
protein and SAP (495% probability) were present in all
cases. Small amounts of IgG with polytypic Ig lambda and
kappa light chains were also noted. IgG included the constant
region of IgG1, IgG2, IgG3, and IgG4. In all cases, MS failed
to detect peptides representing fibrinogen-a, SAA, lysozyme,
TTR, apolipoprotein A-I, or gelsolin.
Gelsolin amyloidosis
Two cases of gelsolin amyloidosis were diagnosed based
on LMD/MS results. LMD/MS of gelsolin amyloidosis cases
showed a large number of spectra of gelsolin in both cases
(Figure 2). The range was from 23 to 35 spectra, with an
average of 33.3 spectra (± 6.0), and 495% probability in
all cases (Figure 3i). In all cases, large spectra (495%
probability) of apolipoprotein E protein were also present.
SAP was also present in all cases; the spectra ranged from
24 to 30, with an average of 26.7 spectra (±3.4). Small
amounts of IgG, IgA, and apolipoprotein A-IV were also
noted. In all cases, MS failed to detect peptides representing
LECT2, fibrinogen-a, SAA, lysozyme, TTR, or apolipo-
protein A-I.
Apolipoprotein amyloidosis
One case of apolipoprotein A-IV amyloidosis, restricted to
the renal medulla, was diagnosed based on LMD/MS
results.11 The most abundant peptides detected represented
apolipoprotein A-IV protein (Figure 2). LMD/MS showed a
large number of spectra of apolipoprotein A-IV ranging from
73 to 103 (495% probability), with an average of 89.6
(±14.5). SAP was also present; the spectra ranged from 16 to
20, with an average of 17.3 spectra (±2.3). Small amounts of
apolipoprotein E and apolipoprotein A-I were also detected.
LMD/MS failed to detect peptides representing TTR, LECT2,
Figure 3 | Continued.
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fibrinogen-a, SAA, apolipoprotein A-II, or significant
immunoglobulin heavy or light chains.
One case of apolipoprotein A-I amyloidosis was diagnosed
based on LMD/MS results. The most abundant peptides
detected represented apolipoprotein A-I protein. LMD/MS
showed a large number of spectra of apolipoprotein A-I
ranging from 28 to 34 (495% probability), with an average
of 30.5 (±2.1). SAP was also present; the spectra ranged
from 13 to 23, with an average of 19.25 spectra (±4.2). Small
amounts of apolipoprotein E and apolipoprotein A-IV were
also detected. MS failed to detect peptides representing TTR,
LECT2, fibrinogen-a, SAA, apolipoprotein A-II, or signifi-
cant immunoglobulin heavy or light chains.
b-2 Microglobulin
A single case of a nephrectomy specimen with multiple
simple cysts consistent with polycystic kidney disease showed
amyloid within tubular casts. Congo red stain was positive
and electron microscopy confirmed the amyloid fibrils within
the casts. LMD/MS detected a peptide profile consistent
with b-2 microglobulin–type amyloid deposition. LMD/MS
showed a large number of spectra of b-2 microglobulin
ranging from 8 to 14, with an average of 11 (±2.4; Figure 3j).
MS failed to detect peptides representing TTR, LECT2, fibri-
nogen-a, SAA, apolipoprotein A-II, or significant immuno-
globulin heavy or light chains.
TTR amyloidosis
A single case of biopsy of the renal pelvis showed TTR
amyloidosis based on LMD/MS results (Figure 2). Subse-
quent workup also showed cardiac involvement. LMD/MS
showed a large number of spectra of TTR ranging from 18 to
32 (495% probability), with an average of 27.25 (±5.4;
Figure 3k). SAP was also present; the spectra ranged from
9 to 20, with an average of 15.6 spectra (±4.5). Small
amounts of IgG, IgA, apolipoprotein A-IV, and apolipo-
protein E were also noted. MS failed to detect peptides
representing LECT-2, fibrinogen-a, SAA, b-2 microglobulin,
gelsolin, or apolipoprotein A-I.
Indeterminate group
We were unable to type five cases of amyloidosis. Of these, two
cases did not show or showed very weak spectra for SAP, thus
questioning the diagnosis of amyloidosis. In the remaining
three cases, LMD/MS showed a large number of SAP spectra,
confirming the diagnosis of amyloidosis. The SAP spectra
ranged from 14 to 42, with an average of 23.3 (±9.1). However,
on retrospective review of the MS data for this manuscript, all
three cases showed large spectra for apolipoprotein A-IV
ranging from 29 to 64 (with 495% probability in all cases),
with an average of 45.9 (±10.5). In addition, the amyloid was
restricted to the interstitium, with no glomerular or vascular
involvement. This raises the possibility of apolipoprotein A-IV
amyloidosis. Apolipoprotein A-IV amyloidosis has only been
recently described11 and was not a defined entity at the time
when LMD/MS was performed in these cases.
Control cases
For comparison, we also performed LMD/MS on glomeruli
of day 0 protocol biopsies of the allograft kidney. We
conducted these studies in 25 cases. The renal biopsy results
were as close to those of normal kidneys on light microscopy
examination. LMD/MS showed large spectra for keratin,
actin, vimentin, actinin, hemoglobin, and smaller spectra for
albumin, histones, hornerin, trypsin (used for digestion
process), etc. The protein spectra of seven representative
cases are shown in Figure 2c. Importantly, none of the
amyloidogenic proteins was found in the day 0 protocol
biopsies.
DISCUSSION
LMD/MS is a relatively new technique used for diagnosis and
typing of amyloidosis. We have described the usefulness of
this technique in unique cases of renal amyloidosis in native
and transplant kidney biopsies.5,10–13 This manuscript is a
comprehensive review of LMD/MS results of 127 cases of
renal amyloidosis. These include all cases of LMD/MS
performed on renal biopsy or nephrectomy specimens from
2008 to 2010. LMD/MS was performed on most cases when
immunofluorescence studies were equivocal or inconclusive
and/or no material was available for immunofluorescence
studies.
The diagnosis of amyloidosis at the proteomic level using
LMD/MS is based on the presence of SAP (Table 2). In all
cases, large spectra of apolipoprotein E are found as well,
suggesting that it may have a role in fibrillogenesis. It should
be pointed out that apolipoprotein E in the amyloid is likely
not due to high serum lipid levels associated with nephrotic
syndrome, as apolipoprotein E is also noted in amyloidosis
Table 2 | Criteria for diagnosis and typing of amyloidosis by
LMD/MS
Peptides on MS (495% probability)
Diagnosis of
amyloidosis
Serum amyloid protein
Apolipoprotein E also present in 100% of cases
AL lambda light
chain
Lambda light-chain C region, with or without V
region; absence of significant kappa light chains
AL kappa light
chain
Kappa light-chain C region, with or without V
region; absence of significant lambda light chains
AH heavy chain Heavy chain: g, m, a, with large number of spectra, in
comparison with light-chain spectra
AA SAA
LECT2 Leukocyte cell–derived chemotaxin-2 (LECT-2)
Fibrinogen-a Fibrinogen-a
Apolipoprotein
A-I or IV
Apolipoprotein A-I or IV, large and predominant
spectra compared with few small spectra often
found in other types of amyloid
TTR Transthyretin (TTR)
Gelsolin Gelsolin
b-2
Microglobulin
b-2 Microglobulin
Lysozyme Lysozyme
Abbreviations: AA, reactive secondary amyloidosis; AH, immunoglobulin heavy-
chain amyloidosis; AL, immunoglobulin light-chain amyloidosis; C, constant; LMD,
laser microdissection; MS, mass spectrometry; SAA, serum amyloid A; V, variable.
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not associated with nephrotic syndrome and high serum lipid
levels, such as amyloid restricted to the renal interstitium or
vessels, and in amyloidosis of other organs such as heart,
liver, etc. Few methylated and oxidized amino acids were also
detected, and it is possible that they were generated during
processing of the sample. The typing of amyloid is then
based on the presence of the spectra that correspond to the
specific type of amyloid. For example, AL lambda light-
chain amyloid contains large spectra of Ig lambda light-chain
C region with or without lambda light-chain V region.
Typically, Ig kappa light chains are absent or very small
spectra of Ig kappa light chain along with heavy chain may be
detected, representing small amounts of polyclonal reabsorp-
tion protein granules and/or entrapment of immuno-
globulins in areas of amyloid. Similarly, AL kappa light-
chain amyloid contains large spectra of kappa light-chain C
region with or without kappa light-chain V region. It is
uncommon to find the hypervariable region in light-chain
amyloid. In the case of AH amyloid, there are large spectra of
the heavy chain with or without an accompanying light-chain
C or V region. In the remaining types of amyloidosis, the
criteria for amyloid typing are even more straightforward
and are based on identification of the specific peptide
spectra belonging to the amyloid type, as these peptides are
not found in the normal proteome of the glomerulus. For
example, AA amyloidosis shows spectra of SAA protein,
LECT2 amyloidosis shows spectra of LECT2 protein,
fibrinogen-a amyloidosis shows spectra for fibrinogen-a
including the mutated fibrinogen A peptide, TTR amyloi-
dosis shows spectra for TTR, and so on. LMD/MS of normal
glomeruli (day 0 protocol kidney biopsies) showed that these
glomeruli do not contain spectra of any of these amyloido-
genic peptides.14
The advantages of LMD/MS over conventional methods
of amyloid typing are multifold: (1) LMD/MS is a single
test that can identify the amyloid protein in question vs.
testing the renal biopsy for individual amyloid proteins via
immunohistochemistry or other ancillary studies. (2) LMD is
performed directly on the involved tissue glomeruli, vessels,
or interstitium, i.e., Congo red–positive areas are dissected.
Thus, LMD/MS is performed on the tissue involved by the
amyloid and not on the entire renal biopsy specimen. This
is in contrast to other tests such as western blot analyses,
which use large amounts of uninvolved tissue as well and
typically screen for a single amyloid protein at a time. There
is also a lack of specificity because the tissue contains non-
amyloid tissue and serum, which may be a rich source of
amyloidogenic proteins. (3) LMD/MS is performed on
paraffin-embedded material and does not require frozen
material. Thus, studies can be conducted on archival
material. We have performed LMD/MS-based diagnosis and
typing of amyloid on 30-year-old paraffin-embedded materi-
al. Inadequate biopsy specimen, especially when there is
limited tissue for immunofluorescence microscopy, is indeed
a common indication for LMD/MS studies for amyloid
typing. (4) Problematic amyloid cases that pose difficulty in
amyloid typing on immunofluorescence studies such as
heavy-chain or heavy- and light-chain amyloidosis are
another important reason for conducting LMD/MS studies.5
We are becoming increasingly aware that many cases of AL
amyloidosis have an AH component based on LMD/MS
studies. Further studies are required to determine whether
the presence of AH component has any effect on treatment,
prognosis, and outcome of immunoglobulin-associated
amyloidosis. (5) Familial and hereditary amyloidosis are
difficult to diagnose on routine immunofluorescence and
immunohistochemistry studies, e.g., LECT2, fibrinogen-a,
and apolipoprotein amyloid. LMD/MS is extremely useful
and sensitive in the diagnosis and typing of cases in which
elaborate and time-consuming genetic analyses are often
required.13 (6) With the current software and database, it is
possible to identify the genetic variants of amyloidogenic
proteins, such as variants of SAA or fibrinogen-a protein.10
(7) LMD/MS can detect and type early amyloid even before
Congo red stain is positive, thus questioning the definition of
amyloid, i.e., amyloid is Congo red positive. Early detection is
based on the presence of SAP protein and the identification
of unique amyloidogenic protein, such as fibrinogen-a or
SAA.12 (8) Monoclonal gammopathy may be present in
patients with non-AL or AH amyloidosis. Some of these cases
are presumed to be AL amyloid. The most common missed
diagnosis is fibrinogen-a amyloid.4 LMD/MS is extremely
useful in such cases to confirm hereditary or other types
of amyloid and rule out AL amyloid in the setting of a
monoclonal gammopathy.
LMD/MS is also helpful in differentiating other causes of
fibrillary deposits from amyloidosis. Fibrillary glomerulone-
phritis shows glomerular fibrillary deposits that are positive
for IgG and light chains that are sometimes monoclonal.15
Such cases of fibrillary glomerulonephritis can be difficult to
differentiate from AH or AHþAL amyloidosis, particularly
when the Congo red staining is equivocal. In such cases,
LMD/MS is extremely useful and will detect spectra of SAP
and heavy and light chains, thus confirming the heavy-chain
amyloid. On the other hand, SAP is typically not detected in
fibrillary glomerulonephritis, and typically large spectra of
heavy chains are present.16 Another potential use of LMD/MS
is in the setting of two or more types of amyloidosis
coexisting together. However, in our practice, we have not
come across such cases. On the other hand, LMD/MS in AA
amyloidosis (diagnosis based on immunohistochemistry
performed at a different institutions), in the setting of
monoclonal gammopathy, confirmed spectra for AL amyloi-
dosis and ruled out AA amyloidosis even though SAA was
positive on immunohistochemistry studies. Similarly, on
LMD/MS, few cases of presumed AL amyloidosis (based on
the presence of a monoclonal gammopathy, as no immuno-
fluorescence studies were conducted or were inadequate), in
fact, revealed fibrinogen-a, LECT2, or apolipoprotein A-IV
amyloidosis.
The common indications for LMD/MS studies included
confirmation of amyloid type, inadequate sample for
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immunofluorescence studies, difficult cases on routine
renal biopsy studies such as heavy-chain amyloidosis, and
familial and hereditary amyloidosis. In many cases, clinicians
directly ordered LMD/MS studies at the time of renal biopsy
for confirmation and typing. Thus, it should be noted that
the amyloid types detected by LMD/MS in this study
represent the challenging cases and are not representative of
the incidence of amyloid types in the population. In our
practice, LMD/MS studies were conducted in B14% of the
renal biopsy specimens for confirmation and typing of
amyloidosis.
This study does not address the LMD/MS performed on
fat-pad aspirate, cardiac tissue, bone marrow tissue, lymph
node, gastrointestinal tract, brain, etc. Obviously, these are
other sites of amyloid deposition, and paraffin-embedded
material from these sites can also be used for amyloid
diagnosis and typing by LMD/MS. In particular, LMD/MS on
the fat-pad aspirate is more appealing, as it is a less invasive
procedure for the diagnosis and typing of amyloidosis.
To summarize, we present the results of LMD/MS
performed on 127 renal biopsies and nephrectomy specimens
for diagnosis and typing of renal amyloidosis over 2-year
period. LMD/MS studies are useful because it uses formalin-
fixed paraffin-embedded tissue instead of fresh, frozen, or
other specially stored tissue samples. Problematic and
challenging biopsies, such as those with equivocal Congo
red staining, equivocal or negative light-chain staining on
immunofluorescence studies, heavy-chain component, and
less common forms such as fibrinogen Aa, TTR, LECT2,
apolipoprotein A-I and A-IV, gelsolin, lysozyme and b-2
microglobulin amyloidosis fall in a group of amyloidosis that
can be accurately typed by LMD/MS.
MATERIALS AND METHODS
Specimen, specimen preparation, LMD, and MS-based
proteomic analysis
MS data of renal biopsies received from 2008 to 2010 in the
Department of Laboratory Medicine and Pathology, Mayo Clinic for
diagnosis and typing of amyloid were analyzed. The Institutional
Review Board at the Mayo Clinic approved the study.
The methods have previously been published.7,8,14 The licensed
Patent Rights to perform protein extraction from paraffin-
embedded tissue for the MS-based amyloid testing have been
granted by Expression Pathology. Briefly, for each case, 10-mm-thick
sections of formalin-fixed paraffin-embedded tissues were stained
with Congo red. Congo red–positive glomeruli viewed under
fluorescent light source appeared bright red. The glomeruli with
Congo red–positive deposits were identified under fluorescent light
and microdissected with LMD using the Leica dissector (Leica DM
600 B). For controls, we used glomeruli from 25 cases of day 0
protocol biopsies of the kidney allograft. The glomeruli were
selected for LMD as shown by the red line. Following LMD, there is
a vacant space on the slide (Figure 1). Each microdissection con-
tained an area of 50,000–60,000mm2, and 2–4 microdissections (typically
two glomeruli per slide, and two slides per case) were analyzed for each
case. Congo red–positive vessels and interstitium were also selected
for microdissection if glomeruli were not available for microdissec-
tion, or if the sample size was felt to be limited. The microdissected
material was collected into 0.5-ml microcentrifuge tube caps
containing 35 ml Tris/EDTA/0.002% Zwittergent buffer. Microdis-
sected fragments were digested into tryptic peptides overnight and
analyzed by liquid chromatography electrospray tandem MS. MS
raw data files were queried using three different algorithms (Sequest,
Mascot and X!Tandem), and the results were combined and assigned
peptide and protein probability scores in Scaffold (Proteome
Software, Portland, OR). For each case, a list of proteins based on
peptides identified by MS was generated. Peptide identifications
were accepted if they could be established at 490.0% probability
as specified by the Peptide Prophet algorithm.17–19 The MS data
show peptides and spectra that match a particular protein based on
the amino-acid sequence available in the database. Some of the
peptides (and spectra) from different proteins can be common and
be shared depending upon the homology of their amino-acid
sequence. On the other hand, unique peptides and spectra are
distinctive to the particular protein. The ‘Spectra’ value indicates the
total number of mass spectra collected on the mass spectrometer
and matched to the protein using the proteomics software. A higher
number of mass spectra is indicative of greater abundance and will
typically yield greater amino-acid sequence coverage. A higher mass
spectra value also indicates a higher confidence in the protein identi-
fication. Our clinical amyloid testing requires a minimum number
of four spectra in all samples before the protein identification will be
deemed clinically valid.
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